(secondQuint)BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer.

 OBJECTIVES: - Determine the objective response rate in patients with locally recurrent or metastatic colorectal cancer treated with BMS-247550.

 - Determine the toxicity of this drug in these patients.

 - Determine the duration of response, median and overall survival, and time to progression in patients treated with this drug.

 OUTLINE: This is a multicenter study.

 Patients receive BMS-247550 IV over 3 hours on day 1.

 Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.

 Patients are followed every 6 weeks.

 PROJECTED ACCRUAL: A total of 21-50 patients will be accrued for this study within 8-10 months.

.

 BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer@highlight

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

 PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have recurrent or metastatic colorectal cancer.

